FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024075791> ?p ?o ?g. }

• W2024075791 endingPage "2670" @default.
• W2024075791 startingPage "2662" @default.
• W2024075791 abstract "Purpose To evaluate the safety and efficacy of liposomal doxorubicin (Myocet; Medeus Pharma Ltd, Herts,UK) when substituted for doxorubicin in the CHOP regimen (cyclophosphamide, doxorubicin, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma (AIDS-NHL). Secondary objectives were to assess the impact of HIV viral control on response and survival, and to correlate MDR-1 expression with outcome. Patients and Methods Liposomal doxorubicin at doses of 40, 50, 60, and 80 mg/m 2 was given with fixed doses of cyclophosphamide, vincristine, and prednisone every 21 days. All patients received concurrent highly active antiretroviral therapy. NHL tissues were evaluated for multidrug resistance (MDR-1) expression. Results Twenty-four patients were accrued. 67% had high or high-intermediate International Prognostic Index scores; the median CD4 lymphocyte count was 112/mm 3 (range, 19/mm 3 to 791/mm 3 ). No dose-limiting toxicities were observed at any level, with myelosuppression being the most frequent toxicity. Overall response rate was 88%, with 75% complete responses (CRs), and 13% partial responses. The median duration of CR was 15.6+ months (range, 1.7 to 43.5+ months). Effective HIV viral control during chemotherapy was associated with significantly improved survival (P = .027), but CRs were attained independent of HIV viral control. MDR-1 expression did not correlate with response, suggesting that the liposomal doxorubicin may evade this resistance mechanism. Conclusion Liposomal doxorubicin in combination with cyclophosphamide, vincristine, and prednisone is active in AIDS-NHL, with complete remissions achieved in 75% independent of HIV viral control or tissue MDR-1 expression. HIV viral control is associated with a significant improvement in survival. Additional studies are warranted." @default.
• W2024075791 created "2016-06-24" @default.
• W2024075791 creator A5005358222 @default.
• W2024075791 creator A5024642865 @default.
• W2024075791 creator A5030671395 @default.
• W2024075791 creator A5046826779 @default.
• W2024075791 creator A5051632521 @default.
• W2024075791 creator A5052181310 @default.
• W2024075791 creator A5067821687 @default.
• W2024075791 creator A5084450647 @default.
• W2024075791 date "2004-07-01" @default.
• W2024075791 modified "2023-10-18" @default.
• W2024075791 title "Liposome-Encapsulated Doxorubicin in Combination With Standard Agents (cyclophosphamide, vincristine, prednisone) in Patients With Newly Diagnosed AIDS-Related Non-Hodgkin's Lymphoma: Results of Therapy and Correlates of Response" @default.
• W2024075791 cites W105359055 @default.
• W2024075791 cites W1528514916 @default.
• W2024075791 cites W1531911812 @default.
• W2024075791 cites W1757115607 @default.
• W2024075791 cites W1776168062 @default.
• W2024075791 cites W1799513092 @default.
• W2024075791 cites W1875822544 @default.
• W2024075791 cites W1911376378 @default.
• W2024075791 cites W1943155210 @default.
• W2024075791 cites W1969795656 @default.
• W2024075791 cites W1992716617 @default.
• W2024075791 cites W2001783515 @default.
• W2024075791 cites W2003623971 @default.
• W2024075791 cites W2013541526 @default.
• W2024075791 cites W2036379838 @default.
• W2024075791 cites W2045133844 @default.
• W2024075791 cites W2055937910 @default.
• W2024075791 cites W2069835659 @default.
• W2024075791 cites W2070739630 @default.
• W2024075791 cites W2073913851 @default.
• W2024075791 cites W2087824134 @default.
• W2024075791 cites W2089639116 @default.
• W2024075791 cites W2097549829 @default.
• W2024075791 cites W2098938825 @default.
• W2024075791 cites W2103970111 @default.
• W2024075791 cites W2118221216 @default.
• W2024075791 cites W2122939659 @default.
• W2024075791 cites W2130375590 @default.
• W2024075791 cites W2131403498 @default.
• W2024075791 cites W2146329405 @default.
• W2024075791 cites W2170776146 @default.
• W2024075791 cites W2227630971 @default.
• W2024075791 cites W2330768369 @default.
• W2024075791 cites W2335295875 @default.
• W2024075791 cites W4205736005 @default.
• W2024075791 cites W4245797813 @default.
• W2024075791 doi "https://doi.org/10.1200/jco.2004.10.093" @default.
• W2024075791 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15226333" @default.
• W2024075791 hasPublicationYear "2004" @default.
• W2024075791 type Work @default.
• W2024075791 sameAs 2024075791 @default.
• W2024075791 citedByCount "70" @default.
• W2024075791 countsByYear W20240757912012 @default.
• W2024075791 countsByYear W20240757912013 @default.
• W2024075791 countsByYear W20240757912014 @default.
• W2024075791 countsByYear W20240757912015 @default.
• W2024075791 countsByYear W20240757912016 @default.
• W2024075791 countsByYear W20240757912018 @default.
• W2024075791 countsByYear W20240757912019 @default.
• W2024075791 countsByYear W20240757912021 @default.
• W2024075791 countsByYear W20240757912022 @default.
• W2024075791 crossrefType "journal-article" @default.
• W2024075791 hasAuthorship W2024075791A5005358222 @default.
• W2024075791 hasAuthorship W2024075791A5024642865 @default.
• W2024075791 hasAuthorship W2024075791A5030671395 @default.
• W2024075791 hasAuthorship W2024075791A5046826779 @default.
• W2024075791 hasAuthorship W2024075791A5051632521 @default.
• W2024075791 hasAuthorship W2024075791A5052181310 @default.
• W2024075791 hasAuthorship W2024075791A5067821687 @default.
• W2024075791 hasAuthorship W2024075791A5084450647 @default.
• W2024075791 hasBestOaLocation W20240757911 @default.
• W2024075791 hasConcept C126322002 @default.
• W2024075791 hasConcept C141071460 @default.
• W2024075791 hasConcept C143998085 @default.
• W2024075791 hasConcept C203014093 @default.
• W2024075791 hasConcept C2776694085 @default.
• W2024075791 hasConcept C2776755627 @default.
• W2024075791 hasConcept C2778720950 @default.
• W2024075791 hasConcept C2779338263 @default.
• W2024075791 hasConcept C2779429289 @default.
• W2024075791 hasConcept C2779725641 @default.
• W2024075791 hasConcept C2781303535 @default.
• W2024075791 hasConcept C2781413609 @default.
• W2024075791 hasConcept C71924100 @default.
• W2024075791 hasConcept C90924648 @default.
• W2024075791 hasConcept C98274493 @default.
• W2024075791 hasConceptScore W2024075791C126322002 @default.
• W2024075791 hasConceptScore W2024075791C141071460 @default.
• W2024075791 hasConceptScore W2024075791C143998085 @default.
• W2024075791 hasConceptScore W2024075791C203014093 @default.
• W2024075791 hasConceptScore W2024075791C2776694085 @default.
• W2024075791 hasConceptScore W2024075791C2776755627 @default.
• W2024075791 hasConceptScore W2024075791C2778720950 @default.
• W2024075791 hasConceptScore W2024075791C2779338263 @default.
• W2024075791 hasConceptScore W2024075791C2779429289 @default.

• next